Edgewise Therapeutics Inc (EWTX) saw an uptrend of 6.26% in the recent trading with $15.62 being its most recent. The current price level -59.02% lower than the highest price of $38.12 marked by the stock while trading over the past 52-weeks, whereas it is 47.36% higher than the lowest price of $10.60 the company dropped to over past 52-weeks. The latest news story on EWTX appeared in (PR Newswire) under the title “Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules”.
Do analysts rate it as a buy, sell or hold?
Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Strong Buy by 1 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 1.46 for the stock.
Edgewise Therapeutics Inc Earnings – What Happened With EWTX
Coming around sales and income figures on EWTX Stock Income Statement, public trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. Edgewise Therapeutics Inc (EWTX) last released financial results for the quarter that ended 9/30/2024, posting a surprise factor of 3.27% for net revenue.
EWTX – Edgewise Therapeutics Inc Stock Earnings Estimates
The perspective of Edgewise Therapeutics Inc (NASDAQ:EWTX)’s current quarter earnings identifies that analysts are in consensus over the estimate of -0.37 for stock’s EPS in the current quarter. Edgewise Therapeutics Inc (EWTX) last released financial results for the quarter that ended 9/30/2024, posting a surprise factor of 3.27% for net revenue. Company’s EPS for the last quarter was -0.36.
Edgewise Therapeutics Inc – Insider Activity and Holdings
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 105.34 million. EWTX does have institutional investors; and they hold 84.45% of the stock.
As on 2024-06-30, ORBIMED ADVISORS LLC was the top most holder in Edgewise Therapeutics Inc (NASDAQ:EWTX) with an ownership of 15.02 million shares of the company or 16.0634 of the stake worth $270.54 million. The filing also reveals RA CAPITAL MANAGEMENT, L.P. as the second largest holder in the company with a control over 9.5269 of the outstanding shares. Its stake is worth $160.45 million for having 8.91 million shares in hand.
NOVO HOLDINGS A/S also came holding a key position in the company during the recent quarter and it now holds 6.7844 of the outstanding shares. With this there are now 255.0 institutions which have possession in EWTX’s shares.
Key Metrics for EWTX
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, Edgewise Therapeutics Inc has a debt to equity ratio of 0.01.
